“The World Health Organization (WHO) on Friday said that Nigeria, Cameroon and Chad, who are in the ‘meningitis belt’ stretching across Africa, will this month introduce a new vaccine designed to eliminate a particular strain of the often deadly disease,” Afrique en ligne reports (12/10). “Alison Brunier, a spokesperson for WHO, told journalists in Geneva that the three countries plan to vaccinate about 22 million people [among] them, focusing on the highest-risk demographic category — those aged between one and 29 years” and that “the immunization campaign should be completed within a couple of weeks,” the U.N. News Centre writes (12/9).

“A statement made available to PANA in New York stated that the countries will vaccinate millions of their citizens with ‘MenAfriVac,’ which was created to target Group A meningitis, responsible for millions of cases in sub-Saharan Africa over the past century,” Afrique en ligne notes (12/10). “A year ago, Burkina Faso became the first country to conduct a nationwide campaign using MenAfriVac, and, according to Brunier, the campaign would be extended to 19 other countries within the belt (Senegal in the West to Ethiopia in the East) by 2016,” Nigeria’s Leadership writes (Oluwarotimi, 12/11).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.